Cold sore herpes medication
Pro Research Analysisby 
Searched over 200M research papers
Cold Sore Herpes Medication: An Overview of Current Treatments
Introduction to Cold Sore Herpes (Herpes Simplex Labialis)
Cold sores, also known as herpes simplex labialis (HSL), are a common viral infection caused by the herpes simplex virus (HSV). They manifest as painful vesicular eruptions on the lips, leading to cosmetic disfigurement and psychosocial distress2. Despite the prevalence of HSL, there is no cure, and the condition tends to recur periodically2.
Topical Treatments for Cold Sores
ME-609 (Xerese, Xerclear)
ME-609, a combination of 5% acyclovir and 1% hydrocortisone, has shown promising results in preventing the progression of cold sores to ulcerative lesions. In a study involving 1443 patients, 42% of those treated with ME-609 did not develop ulcerative lesions, compared to 35% with acyclovir alone and 26% with placebo1. Additionally, ME-609 significantly reduced the cumulative lesion area and healing times compared to both acyclovir and placebo1.
Dynamiclear
Dynamiclear, an over-the-counter topical treatment containing Hypericum perforatum, Calendula officinalis, and copper sulfate, is being evaluated for its efficacy in reducing the duration and severity of HSL episodes. This treatment is currently under investigation in a randomized, double-blind, placebo-controlled trial3.
Kanuka Honey
Kanuka honey-based topical treatment (Honevo) is being compared to 5% acyclovir cream in a randomized controlled trial. The study aims to determine the efficacy of kanuka honey in reducing healing time and pain associated with cold sores. Preliminary results suggest that kanuka honey may offer a viable alternative to traditional antiviral creams4.
Iontophoretic Administration of Acyclovir
A novel approach involves the use of a low-voltage, wireless, hand-held iontophoretic applicator to enhance the skin penetration of topical acyclovir. This method has shown to reduce the median lesion healing time by 1.5 days compared to placebo, with even more significant results in patients treated at the erythema stage5.
Oral Antiviral Treatments
Valacyclovir
Oral valacyclovir, which increases acyclovir bioavailability, has been studied for its effectiveness in treating cold sores. Two randomized, placebo-controlled studies demonstrated that a high-dose, short-duration regimen of valacyclovir significantly reduced the duration of cold sore episodes and the time to lesion healing6 7. The 1-day treatment regimen was particularly effective, reducing the episode duration by 1.0 day and the time to pain cessation by 0.7-0.8 days compared to placebo6 7.
Long-Term Use of Oral Antivirals
Long-term use of oral antiviral agents, such as acyclovir and valacyclovir, has been shown to reduce the recurrence of HSL. Studies indicate that these treatments can decrease both clinical and virological recurrences without increasing adverse events2.
Emerging Treatments
Helicase-Primase Inhibitors
New helicase-primase inhibitors, such as BAY 57-1293, have shown potent in vitro anti-herpes activity and superior efficacy in animal models. These inhibitors significantly reduce healing time, prevent disease rebound, and decrease the frequency and severity of recurrent HSL9. This class of drugs holds significant potential for future treatment options, especially for patients resistant to current medications.
Conclusion
The management of cold sores involves a variety of topical and oral antiviral treatments, each with its own benefits and limitations. ME-609 and iontophoretic acyclovir show promise in enhancing the efficacy of topical treatments, while high-dose, short-duration valacyclovir regimens offer a convenient and effective oral treatment option. Emerging therapies, such as helicase-primase inhibitors, may provide new avenues for managing HSL in the future. Continued research and clinical trials are essential to optimize treatment strategies and improve patient outcomes.
Sources and full results
Most relevant research papers on this topic
Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial.
Topical ME-609 effectively prevents cold sore progression to ulcerative lesions and significantly reduces cumulative lesion area compared to acyclovir and placebo.
RCT
Large Human TrialInterventions for prevention of herpes simplex labialis (cold sores on the lips).
Short-term oral aciclovir use shows inconsistent evidence for preventing recurrent herpes simplex labialis, with uncertain effects of valaciclovir.
Systematic Review
Very Rigorous JournalEfficacy of a topical herbal and mineral formulation (Dynamiclear) for the treatment of herpes simplex labialis in the community setting: study protocol for a randomised, double-blind placebo-controlled trial
Dynamiclear, an over-the-counter topical treatment, may effectively reduce the duration and severity of herpes simplex labialis episodes.
RCT
Rigorous JournalProtocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting
Medical grade kanuka honey-based topical treatment (Honevo) may be more effective than 5% aciclovir cream in reducing healing time and pain of cold sores.
RCTLarge Human TrialRigorous JournalTopical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial.
Single-dose topical iontophoresis of acyclovir appears to be a convenient and effective treatment for cold sores, warranting further clinical investigation.
RCTRigorous JournalHigh-Dose, Short-Duration, Early Valacyclovir Therapy for Episodic Treatment of Cold Sores: Results of Two Randomized, Placebo-Controlled, Multicenter Studies
A 1-day valacyclovir treatment regimen is a safe and effective alternative for cold sores, reducing episode duration and pain and discomfort.
RCT
Highly CitedRandomized clinical study comparing Compeed® cold sore patch to acyclovir cream 5% in the treatment of herpes simplex labialis
Compeed® cold sore patch effectively treats herpes simplex labialis outbreaks, providing wound-healing benefits and a better treatment option than acyclovir cream 5%.
RCTWhat is the best treatment for herpes labialis?
Valacyclovir is the most effective treatment for herpes labialis, with one-day treatment reducing lesion duration and pain, while famciclovir is effective for recurrent outbreaks.
RCTLarge Human TrialNew helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
BAY 57-1293 shows potential as a well-tolerated, non-nucleosidic anti-herpes drug that reduces recurrence and healing time in herpes simplex patients.
Highly Cited